Law Offices of Frank R. Cruz Encourages Inspire Medical Systems, Inc. (INSP) Shareholders to Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, inclusive (the “Class Period”). Inspire investors have until January 5, 2026 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR INSPIRE MEDICAL SYSTEMS, INC. (INSP) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at [e-mail], by telephone at [phone], or visit our website at www.frankcruzlaw.com.

What Happened?

On August 4, 2025, Inspire disclosed that the launch of its new sleep apnea device, the Inspire V, was facing an “elongated timeframe” due to several issues, including “many centers [not completing] the training, contracting and onboarding criteria required prior to the purchase and implant of Inspire V,” “software updates for claims submissions and processing” not taking effect until early July, and excess inventory causing poor demand. Further, the Company reduced its 2025 earnings guidance by more than 80%, from $2.20 to $2.30 per share to $0.40 to $0.50 per share.

On this news, Inspire’s stock price fell $42.04, or 32.4%, to close at $87.91 per share on August 5, 2025, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) demand for Inspire V was poor, as providers had significant amounts of surplus inventory and were reluctant to transition to a new treatment; (2) Inspire failed to complete training and onboarding for “many” of its treatment center customers; failed to set up basic IT systems, including a customer approval process; failed to ensure that critical insurer claims software was properly updated to facilitate claims processing and payment; and failed to ensure that Medicare reimbursement was in place at the time of the launch; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you purchased Inspire common stock, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:

Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: [phone]
Email: [e-mail]
Visit our website at: www.frankcruzlaw.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.